Your browser doesn't support javascript.
loading
Molecular dynamics simulation study of effects of key mutations in SARS-CoV-2 on protein structures
Jerome Rumdon Lon; Binbin Xi; Bingxu Zhong; Yiyuan Zheng; Zixi Chen; Ruoran Qiu; Siqing Zhang; Pei Guo; Hongli Du.
Afiliación
  • Jerome Rumdon Lon; South China University of Technology; Shenzhen Institute of Advanced Technology
  • Binbin Xi; South China University of Technology
  • Bingxu Zhong; South China University of Technology
  • Yiyuan Zheng; South China University of Technology
  • Zixi Chen; South China University of Technology
  • Ruoran Qiu; South China University of Technology
  • Siqing Zhang; South China University of Technology
  • Pei Guo; South China University of Technology
  • Hongli Du; South China University of Technology
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-429495
ABSTRACT
SARS-CoV-2 has been spreading rapidly since 2019 and has produced large-scale mutations in the genomes. The mutation in genes may lead to changes in protein structure, which would have a great impact on the epidemiological characteristics. In this study, we selected the key mutations of SARS-CoV-2 from a real-time monitoring tool, including D614G, A222V, N501Y, T716I, S982A, D1118H of spike (S) protein, and performed molecular dynamics (MD) simulations on single-site mutant D614G, double-site mutant D614G&A222V and penta-site mutant N501Y&D614G&T716I&S982A&D1118H to investigate their effects on protein structure and stability using molecular dynamics (MD) simulations. The results suggested that D614G improved the stability of S protein, while D614G&A222V and N501Y&D614G&T716I&S982A&D1118H showed an increased solvent accessible surface area and they might enhance the ability of protein to react with the outside environment. Our findings could complement the mechanistic link between genotype--phenotype--epidemiological characteristics in the study of SARS-CoV-2. We also found no significant difference between the antigenicity of S protein and the mutants through Ellipro, which may reference for vaccine development and application.
Licencia
cc_by_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Experimental_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Experimental_studies Idioma: En Año: 2021 Tipo del documento: Preprint